India, Nov. 20 -- Xeris Biopharma Holdings Inc. (XERS) is targeting a significant scale-up in its commercial business, with an ambitious goal of achieving blockbuster revenue by 2030. Buoyed by the strong performance of its marketed products, the company appears to have turned a new page in its growth story.
This biopharmaceutical company focuses on developing and commercialising therapies for people with chronic endocrine and neurological diseases. Its marketed products include Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis.
Beyond its marketed products, the company is advancing its ...